Vaccine mismatch is one of the most consequential—and underappreciated—variables in seasonal influenza protection. When circulating strains drift antigenically from the formulated vaccine, effectiveness can drop sharply even in vaccinated populations, raising hospitalization risk across all age groups. The 2025-2026 season appears to have delivered exactly that scenario, with real-world surveillance data now quantifying the gap.
A JAMA Network Open surveillance study drawing on data from roughly 300 clinical and 100 public health laboratories, the Influenza Hospitalization Surveillance Network (covering approximately 10% of the U.S. population), and a test-negative case-control network found that influenza A(H3N2) subclade K—formally designated J.2.4.1—predominated throughout the 2025-2026 Northern Hemisphere season through mid-March 2026. Researchers characterized the antigenic and genetic properties of subclade K, assessed its susceptibility to approved antivirals, and examined how well post-vaccination antibody responses in 2025-2026 vaccine recipients neutralized it. Vaccine effectiveness estimates were derived from the Virtual SARS-CoV-2, Influenza, and Other Respiratory Viruses Network. The excerpt does not disclose final numerical estimates, hospitalization burden totals, or antiviral susceptibility outcomes—details available in the full publication.
H3N2 seasons historically produce the heaviest disease burden and the most problematic antigenic evolution of any influenza subtype, making subclade K's dominance a meaningful public health signal. The egg-based manufacturing process used for most influenza vaccines introduces well-documented adaptive mutations that can further erode strain-to-vaccine match, a confound that likely influenced the serologic immunogenicity findings here. This is a large, multi-source surveillance study rather than a randomized trial, so vaccine effectiveness estimates carry the inherent limitations of observational designs, including residual confounding by health-seeking behavior. Still, CDC-linked, nationally representative networks of this scale provide some of the most policy-relevant real-world data available. The implications for the 2026-2027 strain selection cycle are direct: subclade K's trajectory will almost certainly factor into WHO and FDA advisory committee deliberations on next season's formulation.